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Objective: Autogenous saphenous vein is the ideal conduit for lower extremity revascularization. Unfortunately, autog-
enous vein is unavailable in up to 20% of patients. Synthetic grafts provide an alternative; however, their use in distal
revascularization has shown varying results. In addition, infected surgical sites preclude their use. Currently, there are
limited outcome data for cryopreserved saphenous vein use in regard to long-term patency and limb salvage rates.
Methods: Cryopreserved saphenous vein allograft use in infrainguinal bypass was studied retrospectively in a community
setting. End points included primary patency, limb salvage, and early complications. Records of patients receiving cry-
opreserved allografts by nine vascular surgeons within one hospital system from 2006 to 2012 were reviewed.
Results: Fifty-three patients, mean age 69 years (standard deviation, 12.3; range, 28-90 years), underwent 60 operations.
Indications for surgery included limb-threatening ischemia (48%), tissue loss (30%), previous graft or site infection (10%),
claudication (7%), or other (5%). The mean follow-up period was 23.9 months (standard deviation, 21.0; range,
0-64 months). Primary patency was maintained in 53% of patients at 1 year and in 22% at 3 years. Limb salvage was
achieved in 74% of patients at 1 year and in 70% at 2 years. Thirteen early complications included 8 thromboses, 2 deaths,
2 amputations, and 1 anastomotic disruption. Fifteen patients (28%) underwent additional ipsilateral operations with use
of synthetic conduits after initial cryopreserved allografts failed.
Conclusions: Cryopreserved vein allografts displayed poor short-term and long-term patency, whereas limb salvage rates at
1 and 2 years remained acceptable. However, >25% of patients required additional ipsilateral operations with use of
synthetic conduits after previous failed cryopreserved allograft use. Our data indicate that cryopreserved vein graft is a
suboptimal choice of conduit in a noninfected ﬁeld. (J Vasc Surg 2014;60:1291-6.)Autogenous saphenous vein is the ideal conduit for
lower extremity revascularization. Unfortunately, single-
segment autogenous saphenous vein is unavailable in up
to 20% of patients due to previous harvesting, inadequate
size, structural defects, or previous phlebitis.1 In addition
to native saphenous vein, alternative vein conduits, such
as cephalic, basilic, and small saphenous veins, are unavai-
lable in 10% of patients.1,2 Prosthetic grafts remain a
reasonable option for above-knee revascularizations but
have performed poorly when used for distal or infragenicu-
late revascularization. In an attempt to improve patency
and limb salvage in this difﬁcult circumstance, techniques
including distal vein cuff, spliced vein segment conduits,
heparin-bonded polytetraﬂuoroethylene (PTFE) grafts,
and arteriovenous ﬁstula (AVF) creation have been
reported.
Distal anastomotic vein cuff techniques have been used
with regularity as means of preventing or slowing neointi-
mal hyperplasia, the main culprit for most graft failures.the Department of Surgery, Mount Carmel Health System.
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://dx.doi.org/10.1016/j.jvs.2014.05.092Two randomized trials have presented contradictory evi-
dence in regards to whether distal vein cuff use confers a
beneﬁt in below-knee synthetic graft primary patency.
Stonebridge et al3 found statistically signiﬁcant differences
in primary patency at 12 and 24 months when distal vein
cuff in conjunction with PTFE graft was used for below-
knee popliteal bypass. However, no signiﬁcant differences
were found in limb salvage for similar time periods.3 In a
similar study however, no statistically signiﬁcant difference
for primary patency or limb salvage was appreciated at
36 months in below-knee popliteal or femoral-tibial
PTFE bypass with use of distal vein cuff.4
A ﬁnal study by Panneton et al5 in 2004 evaluated pre-
cuffed PTFE graft performance vs PTFE graft with distal
vein cuff use. Evidence from this randomized trial sug-
gested no signiﬁcant difference in primary patency, second-
ary patency, or limb salvage rates between the two
techniques. Operative time was shorter in the precuffed
group, but this difference failed to reach statistical signiﬁ-
cance. Vein cuff use with PTFE graft was felt to be more
technically demanding while conferring little or no signiﬁ-
cant advantage in outcomes.5
When single-segment autogenous saphenous vein is
unavailable, spliced vein bypass conduits created from re-
sidual great saphenous vein, small saphenous vein, arm
vein (basilic or cephalic), or combinations of these remain
an option. Kreienberg et al6 studied spliced vein bypass
graft performance compared with PTFE with distal vein
cuff in a randomized fashion. No statistically signiﬁcant dif-
ferences in primary patency or limb salvage rates were
found between the two groups. Although secondary1291
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group at 24 months, signiﬁcantly longer operative time,
greater blood loss, and longer hospital stays were also
demonstrated. Finally, the spliced vein group required
reoperation more frequently due to a higher prevalence
of wound complications.6
In addition to neointimal hyperplasia creating high
outﬂow resistance and subsequent graft failure, thrombotic
graft occlusion caused by low blood velocities remains a
signiﬁcant issue. AVF creation near the distal anastomoses
may be used to address this problem. Two randomized tri-
als, from Hamsho et al7 and Laurila et al,8 studied out-
comes for below-knee PTFE bypass with distal vein cuff
use in those with and without adjuvant AVF creation.
Both studies found no effect on outcomes, including pri-
mary patency, secondary patency, or limb salvage rates, at
24 months. Furthermore, immediate reoperation and graft
occlusion rates were similar between groups, whereas the
construction of the adjuvant AVF increased the operative
time signiﬁcantly.7,8
Cryopreserved saphenous vein allograft remains an
additional conduit option for use in below-knee revascular-
ization. Short-term outcomes for allograft use and perfor-
mance remain mixed in the literature. In 2001, Harris
et al9 reported long-term primary patency rates of 37% at
1 year and 24% at 3 years and a limb salvage rate of 65%
during similar time intervals. Only a minority of patients
had acutely threatened limbs, and tissue loss served as the
main indication for surgical revascularization. A signiﬁcant
number of patients studied required early reoperation, and
poor wound healing persisted despite surgical intervention.
The authors recommended allograft use only after the
search for autologous vein had been exhausted and strong
consideration for PTFE conduit use with adjuvant distal
vein cuff.9
A smaller study by Buckley et al10 cited exceedingly
high 1-year and 2-year primary patency rates of 87% and
82%, respectively, for cryopreserved saphenous vein allo-
graft use in infrapopliteal revascularization. In addition to
a small sample size (n ¼ 24), postoperative medical therapy
was extensive, involving use of daily aspirin, low-dose hep-
arin, dextran, dipyridamole, and warfarin. Finally, indica-
tions for surgery in this study included no patients with
acutely threatened limbs.10
To date, available outcomes data for allograft use
remain variable at best and limited due to small sample
size.11 On the basis of anecdotal poor performance of cry-
opreserved saphenous vein allograft use for below-knee
revascularization, we retrospectively reviewed its use at
our institution during the last 6 years.
METHODS
A retrospective review was performed of infrainguinal
bypass procedures using cryopreserved saphenous vein allo-
grafts. After Investigational Review Board approval, medi-
cal records were identiﬁed for review by querying hospital
system database for records of implanted allograft saphe-
nous vein (CryoVein; CryoLife, Kennesaw, Ga). This wasa retrospective study based on chart review and patient
consent was waived. Nine vascular surgeons performed
60 operations on 53 patients during a 6-year period
(January 2006 to January 2012). All operations were per-
formed in a community hospital setting, which included
three institutions within the Mt. Carmel Health Hospital
System in Columbus, Ohio.
Demographics obtained included age, sex, and race.
Comorbidities recorded included smoking status, diabetes,
hypertension, hyperlipidemia, coronary artery disease, renal
failure, and pulmonary disease. Comorbidities were deﬁned
as the presence of “active” diagnoses in the medical record
#6 months from the time of surgery. A history of ipsilateral
revascularization, including endovascular and open proce-
dures, was recorded in addition to postoperative use of
antiplatelet, anticoagulation, and immunosuppression ther-
apy. The mean follow-up period was 23.9 6 2.9 months.
Postoperative follow-up and surveillance varied by surgeon,
without a standard surveillance protocol in place. Operative
details obtained included operative time, blood loss, and
distal bypass target vessel.
Primary outcomes included primary patency, limb
salvage, and early complications. Primary patency was
deﬁned as uninterrupted patency after the index operation
without revision of the revascularization to prevent
impending occlusion or progression of stenosis. This was
determined by reviewing patient records, including surveil-
lance duplex imaging, angiograms, physical examinations,
and a review of the medical record documentation. Simi-
larly, record review was used to determine limb salvage as
the time from the index operation until any level amputa-
tion on the ipsilateral limb. Lastly, early complications
were those occurring #30 days of the procedure, including
death, amputation, graft thrombosis, and open or endovas-
cular reintervention.
Demographics, comorbidities, and complications were
descriptively characterized with arithmetic means. The
standard deviation was reported for continuous measures,
and frequency and percentages were reported for categoric
measures. Descriptions of graft patency and limb salvage
rates over time were assessed by Kaplan-Meier curves.
Censored data for life-table analysis included patient deaths
and those lost to follow-up. Grafts were considered patent
and limbs intact up to the time censored if medical records
adequately reﬂected so. Calculations and analyses were per-
formed using Excel (Microsoft Corp, Bellingham, Wash)
and Minitab 15 (Minitab Inc, State College, Pa) software.
RESULTS
From January 2006 to January 2012, 53 patients un-
derwent 60 operations in which cryopreserved saphenous
vein allograft was used. The study population was
composed of 33 men (62%) and 20 women (38%), with
mean age of 69 years (standard deviation, 12.3; range,
28-90 years) at the time of surgery. The study included
47 Caucasians (89%) and six African Americans (11%),
and36patients (68%)were active smokers. Study population
comorbidities are provided in Table I.
Table I. Population comorbidities
Comorbidities Patient, No. (%)
Diabetes 27 (51)
Hypertension 48 (91)
Hyperlipidemia 46 (87)
Coronary artery disease 36 (68)
Renal failure 8 (15)
Pulmonary disease 15 (28)
Table II. Postoperative medical management
Postoperative medical management Patients, No. (%)
Antiplatelet and anticoagulation use
Antiplatelet only 18 (30)
Anticoagulation only 19 (32)
Both 19 (32)
Neither 4 (7)
Table III. Distal target vessels
Distal target vessel Patients, No.
Below-knee popliteal 10
Tibioperoneal trunk 5
Anterior tibial 19
Posterior tibial 15
Peroneal 5
Dorsalis pedis 3
Other
EIA-SFA 1
Above-knee interposition 1
Above-knee popliteal 1
EIA, External iliac artery; SFA, superﬁcial femoral artery.
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vein mapping in which no suitable autologous vein was
identiﬁed according to ultrasound characteristics. In addi-
tion, 13 patients had operative records indicating no autol-
ogous lower extremity vein was available secondary to
previous harvesting. For the remaining 30 patients, no re-
cords of preoperative lower extremity vein mapping nor
operative reports indicating inadequate vein size were
found after a record review. Finally, no upper extremity
vein mapping studies were conducted preoperatively.
Postoperative antiplatelet and anticoagulation use var-
ied and was left to surgeon discretion (Table II). No pa-
tients received immunosuppression therapy after allograft
implantation. A review of the available medical records
showed an average of 1.7 6 0.4 operations had been pre-
formed on the ipsilateral extremity studied. Indications for
surgery included limb-threatening ischemia (48%), tissue
loss (30%), previous graft or site infection (10%), claudica-
tion (7%), and other (5%). Other indications for surgery
included two patients with native artery aneurysmal disease
necessitating resection with revascularization and a ﬁnal pa-
tient with limb-threatening ischemia secondary to Berger
disease.
Distal target vessel revascularization with cryopreserved
allograft was infrageniculate in all procedures with the
exception of three (Table III). The ﬁrst case of above-
knee use included allograft interposition from an external
iliac artery to superﬁcial femoral artery (SFA) after excision
of a native common femoral artery pseudoaneurysm. The
second case involved allograft use to reconstruct an aneu-
rysmal segment of previously placed native vein conduit
(SFA-to-posterior tibial artery) at an above-knee location.
Lastly, allograft was used for bypass to an above-knee
popliteal artery from a previously placed limb of an aorto-
bifemoral prosthetic graft. Average length of hospitaliza-
tion was 9 days, operative time was 207 minutes, and
blood loss was 276 mL.
Primary patency was maintained in 53% of patients at
1 year and in 22% at 3 years (Fig 1). Limb salvage at
1 year was achieved in 74% of patients. Limb salvage could
not be analyzed at a 3-year interval due to signiﬁcant
amounts of censored data creating standard error values
>10%. However, limb salvage was observed in 70% of pa-
tients studied at 24 months (Fig 2). Censored data
regarding primary patency was signiﬁcant after the 21-
month mark despite standard error values remaining
acceptable (<10%) beyond this time frame. A morerepresentative description of graft performance is the 21-
month primary patency (36%) due to a signiﬁcant patient
drop out beyond this point.
Thirteen early complications included 8 thromboses, 2
deaths, 2 amputations, and 1 anastomotic disruption.
Documented deaths were cardiac in etiology and appeared
unrelated to lower extremity ischemia. Eight early graft
thromboses occurred an average of 6.8 days (range, 0-
29 days) from the time of allograft placement. Two acute
occlusions were managed with subsequent revasculariza-
tion using synthetic conduit. An additional 13 patients
(28% overall) after 30 days required further ipsilateral revas-
cularization with synthetic conduits for failed cryopreserved
saphenous vein. Finally, one early anastomotic disruption
was noted at 29 days that required graft ligation without
revascularization.
Owing to signiﬁcant numbers of patients lost to follow-
up beyond the 24-month period, Cox regression analysis
could not be performed for the study group. Before a 1-
month time interval, number of previous surgeries, indica-
tion for surgery, and presence of medical comorbidities did
not appear to signiﬁcantly effect likelihood of early graft
failure.
DISCUSSION
Cryopreserved saphenous vein allograft remains an
additional option for use in below-knee revascularization.
On the basis of anecdotal poor performance of cryopre-
served saphenous vein allograft at our institution, we
sought to retrospectively review its use during the last
6 years. Cryopreserved vein allografts displayed poor
short-term and long-term patency for infrageniculate
Fig 1. Kaplan-Meier plot shows primary patency. The standard error bars depict the upper and lower 95% conﬁdence
interval (CI).
Fig 2. Kaplan-Meier plot shows limb salvage. The standard error bars depict the upper and lower 95% conﬁdence
interval (CI). *Indicates standard error values >10%.
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ported patency rates in the literature. Although 1-year
and 2-year limb salvage remained acceptable, >25% of pa-
tients required additional ipsilateral operations with use of
synthetic conduits. On the basis of previously reported
literature for infrageniculate revascularization using
PTFE, it is reasonable to expect 1-year and 3-year primary
patency rates of up to 65% and 43% for femoral to below-
knee popliteal bypass and 44% and 21% for femoral-tibial
bypass.1,2
We recognize using historical patency data for clinical
comparison can be misleading due to confounding factorssuch as patient comorbidities, clinical scenarios, and several
more. A control group from our institution would have
strengthened this study, but we believe it is safe to assume
our experience with cryopreserved saphenous vein allograft
and its performance falls far short of standard expectations.
There are several plausible explanations for this observed
poor performance. First, nearly half of our patients under-
went placement of allograft for acutely threatened limbs in
the setting of multiple previous ipsilateral operations. Sec-
ond, postoperative medical management with antiplatelet
and anticoagulation use was highly variable and surgeon
dependent. Incomplete medical records combined with
JOURNAL OF VASCULAR SURGERY
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antiplatelet or anticoagulation use in 7% of the patients
studied.
Despite our observed poor primary patency rates, 1-
year and 2-year limb salvage remained acceptable given
that >25% of patients required additional ipsilateral opera-
tions with synthetic conduits after allograft failure. The lack
of cryopreserved allograft efﬁcacy coupled with a signiﬁcant
cost burden draws serious concern about its indication
for use. With recent awareness heightened concerning
cost-containment practices, allograft usage costing nearly
10-fold that of synthetic alternatives, without perceived
performance improvement, is difﬁcult to justify.12
Mixed results on performance in the reported literature
coupled with variable postoperative management, including
some advocating for adjuvant immunosuppression therapy,
are additional factors to consider when contemplating allo-
graft use for lower extremity revascularization. Improved
patency of cryopreserved venous allografts has been re-
ported with low-dose immunosuppression therapy added
to anticoagulation protocols. However, in addition to the
potential systemic side effects of immune suppression, a
higher incidence of pseudoaneurysm formation and resul-
tant graft hemorrhage was reported.13
Numerous anecdotal reports of poor vein quality, vary-
ing preservation techniques, endothelial denuding, and
early aneurysmal degeneration with graft failure are argu-
ments some surgeons cite against its use.14 However, on
the basis of our ﬁndings and many case reports reviewed,
the most beneﬁcial role of cryopreserved venous allografts
appears to be that in which an infected surgical ﬁeld neces-
sitates it use. Our study included six patients for which
infected surgical ﬁelds prompted allograft use. Three pa-
tients had patent grafts at the time of data collection,
whereas two patients underwent subsequent revision with
prosthetic conduits 8 months after their index revasculari-
zation. The ﬁnal patient died 6 months later of an illness
unrelated to the operation. Although no ﬁrm recommen-
dation can be made given this small patient subset, cryopre-
served allograft use is an attractive option for deﬁnitive or
temporary revascularization in the setting of infected surgi-
cal ﬁelds.
For 7% of our patient population, claudication served
as the indication for revascularization using cryopreserved
saphenous vein allograft. Our record review shows this se-
lection appeared to be based solely on surgeon preference.
When considering graft performance and cost, cryopre-
served vein allograft use was a poor clinical decision in
this setting.
Finally, this review demonstrated extensive use of open
intervention for complex patients mostly presenting with
acutely threatened limbs. A valid concern raised is the
lack of endovascular interventions in this population.
Because this study covers multiple surgeons, individual
practices and algorithms vary. In general, the surgeons of
the group are all fully trained in endovascular techniques,
and the group has generally adopted an “endovascularﬁrst” approach. However, the decision on revascularization
strategy is often complex and takes into account multiple
variables such as age, ambulatory status, Trans-Atlantic In-
ter-Society Consensus guidelines, personal experience, pa-
tient preference, and patency rates quoted in literature
and based on personal experience. The retrospective nature
of the current study places limits on uncovering thought
processes of individual surgeons for why cryopreserved
vein was used. Any future prospective studies would take
this into account.
CONCLUSIONS
The obvious shortcomings to this study are, ﬁrst, its
retrospective nature. We cannot be certain all amputations,
revascularizations, patient follow-up, and deaths occurred
within our system. Other signiﬁcant issues are variable
postoperative management, multiple surgeons, nonuni-
form availability of graft surveillance imaging postopera-
tively, and lack of an established runoff score to quantify
extent and severity of disease.
Although cryopreserved saphenous vein allograft use
for lower extremity bypass is not a novel concept, we report
one of the larger retrospective studies assessing its use and
performance over a long-term period. We chose to include
the three above-knee revascularization patients in this
study. One would expect that including these above-knee
outcomes would falsely elevate our reported patency rates.
Given our demonstrated poor graft performance, that this
is the case is highly unlikely.
We believe the conclusion of overall poor allograft per-
formance can be made despite its use over a wide range of
clinical indications, including occlusive and aneurysmal dis-
ease. We provide a real-world setting of graft use at our
institution. Our conclusion that graft patency is poor is
an honest evaluation for the diverse manner in which it
was used.
The aforementioned limitations of the retrospective
study limit our ability to study factors predisposing allograft
to failure. If anything, our data would lead us to a prospec-
tive study for evaluation of subgroup analyses. These consid-
erations would be important for a future prospective study
following the historical performance of this graft at our insti-
tution. Despite these ﬂaws, we strongly believe our data
indicate cryopreserved saphenous vein allograft is a subopti-
mal initial choice of conduit in noninfected surgical ﬁelds.
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